Evaluating the impact of atezolizumab on febrile neutropenia occurrence in patients with NSCLC undergoing chemotherapy in Japan: a real-world post-marketing database study
The incidence of FN was higher in the exposure group. Considering the study results, special caution is needed for FN occurrence in patients receiving atezolizumab.
Authors
- Yasuhiro Igarashi (ORCID: https://orcid.org/0000-0001-5114-1389)
- Akinori Yuri
- Kana Yamada (ORCID: https://orcid.org/0000-0003-1328-6477)
- Sayuri Nakane (ORCID: https://orcid.org/0009-0001-2733-3265)
- R. Harada
- Yuki Miyano
- N. Takei
- Erika Nakatsuji
Institutions
- Chugai Pharma (United States) (US)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2024-12-16
- DOI
- https://doi.org/10.1007/s10147-024-02669-y
- Citations
- 2
- Primary Topic
- Neutropenia and Cancer Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Chugai Pharmaceutical